/logo-16545883420.png){kind=logo}
Shenogen’s Jun Bao Attends 2014 ASCO Annual Meeting
May 25th 2014, Beijing, China
The 50th ASCO (American Society of Clinical Oncology) annual meeting will be held on May 30th – June 3rd 2014 in Chicago, USA. Dr. Jun Bao, Senior Vice President & Chief Business Officer of Shenogen Pharma Group, will attend the event. On behalf of Shenogen, Dr. Bao aims to keep up with the cutting-edge scientific findings in oncology field, and maintain the connections with colleagues from around the world.
About Shenogen
Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.